Sidhu v. Bayer Healthcare Pharmaceuticals Inc.

Background

Priya Sidhu sued Bayer Healthcare Pharmaceuticals Inc. individually and on behalf of proposed nationwide and California classes. She alleged that Bayer manufactures and sells the Mirena intrauterine device, marketed for birth control, while failing to disclose studies that she said showed users faced about a 20% to 30% increased risk of breast cancer. Sidhu alleged that her doctor did not know about the alleged risk, that Bayer’s materials stated there was no evidence of increased risk for women like her, and that she would not have used or paid $50 for the device had the risk been disclosed.

The First Amended Complaint asserted nationwide claims for breach of the implied warranty of merchantability, unjust enrichment, and fraud. It also asserted California subclass claims under California’s Unfair Competition Law, Consumers Legal Remedies Act, and False Advertising Law. Bayer moved to dismiss and to strike the class allegations.

Judicial Notice

The court granted Bayer’s request to take judicial notice of seven documents, including Food and Drug Administration prescribing materials and the five publicly available studies cited in the complaint. The court stated that it could notice the documents’ existence and contents but would not treat disputed facts within them as established for purposes of the motion.

Standing

The court denied Bayer’s request to dismiss for lack of Article III standing. It held that Sidhu adequately alleged an economic injury because she claimed she paid for a product she would not have bought if Bayer had disclosed the alleged breast-cancer risk. The court also found that her allegations sufficiently showed causation and redressability.

The court further denied dismissal based on the proposed nationwide class. Because Sidhu adequately alleged individual standing for her California-law claims, the court treated whether she could adequately represent people outside California as a class-certification issue rather than a standing issue at the pleading stage.

Federal Preemption

Bayer argued that federal drug-labeling law preempted Sidhu’s claims because Bayer could not change Mirena’s warnings without Food and Drug Administration approval. The court rejected the argument at the pleading stage. It concluded that Sidhu adequately alleged that studies published after Bayer’s 2015 submission to the agency constituted newly acquired information and provided reasonable evidence of a causal association between Mirena and increased breast-cancer risk.

The court also found no clear evidence that the agency would have rejected a warning change. It therefore denied Bayer’s motion to dismiss the claims as preempted by the federal Food, Drug, and Cosmetic Act.

Equitable Relief

The court granted Bayer’s motion to dismiss the equitable claims for lack of equitable jurisdiction. Equitable relief is unavailable when a plaintiff has an adequate legal remedy. The court found Sidhu’s allegations insufficient to show that legal remedies were inadequate, particularly because her alleged injury was overpayment for a product she would not have purchased absent the alleged misrepresentations and omissions.

The court dismissed Sidhu’s unjust-enrichment claim and her claims under California’s Unfair Competition Law and False Advertising Law. It also dismissed her Consumers Legal Remedies Act claim to the extent it sought equitable relief. The court did not dismiss the Consumers Legal Remedies Act claim insofar as it sought legal remedies.

Learned Intermediary Doctrine

The learned intermediary doctrine generally provides that, for drugs or medical devices supplied through a physician-patient relationship, the manufacturer’s duty to warn runs to the physician rather than directly to the patient. The court held that the doctrine barred Sidhu’s claims to the extent they were based on a duty to warn patients directly. It granted Bayer’s motion to dismiss on that ground. The court did not apply the doctrine to claims based on an alleged failure to warn physicians.

Claims That Remained

The court denied Bayer’s motion to dismiss Sidhu’s fraud and Consumers Legal Remedies Act claims based on alleged misrepresentations and omissions. It found that Sidhu adequately alleged that Bayer’s label language about the absence of conclusive evidence of increased breast-cancer risk was false or misleading in light of the studies identified in the complaint. The court also found sufficient allegations of intent to defraud and a duty to disclose based on Bayer’s alleged superior knowledge and its alleged awareness of the studies.

The court denied dismissal of the implied-warranty claim. Sidhu alleged that the claimed breast-cancer risk made Mirena unsafe and unsuitable for its ordinary purpose, and Bayer’s argument required evaluating the scientific studies in a way the court considered inappropriate at the motion-to-dismiss stage.

Punitive Damages and Class Allegations

The court denied Bayer’s motion to dismiss or strike Sidhu’s punitive-damages request. It found that the complaint’s allegations of willful and malicious conduct were sufficient at this stage.

The court also denied Bayer’s motion to strike the class allegations. It held that the complaint did not demonstrate that a class action could not be maintained under the alleged facts, and that the class-certification issues were premature for resolution on the pleadings.

Disposition

The court denied Bayer’s motions based on standing and federal preemption. It granted Bayer’s motion to dismiss the equitable claims and claims based on a duty to warn patients directly. It denied Bayer’s motion to dismiss the remaining warranty, fraud, and Consumers Legal Remedies Act claims seeking legal remedies, denied the motion concerning punitive damages, and denied the motion to strike the class allegations.